<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448785</url>
  </required_header>
  <id_info>
    <org_study_id>CS-007-P</org_study_id>
    <nct_id>NCT01448785</nct_id>
  </id_info>
  <brief_title>Abiliti™ Treatment in Obese Subjects</brief_title>
  <official_title>Abiliti™ Treatment in Obese Subjects: A Randomized Post-Market Surveillance Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IntraPace, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IntraPace, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this post-market surveillance study is to compare the subject's weight
      loss and quality of life, and device safety performance of the abiliti System and the
      adjustable gastric banding therapies in obese to morbidly obese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to provide additional data regarding the performance and safety of the
      abiliti system in comparison to gastric banding. The composite end-point of the study is
      designed to provide a direct comparison of the effectiveness of the devices for the treatment
      of obesity while giving consideration to the safety profile for each device and their impact
      on patient quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of the abiliti therapy compared to adjustable gastric banding</measure>
    <time_frame>12 months</time_frame>
    <description>The non-inferiority of the abiliti therapy compared to adjustable gastric banding will be measured using a composite endpoint at the end of the study period. The success criteria will be the percentage of subjects in each group who meet all of the following criteria:
Achieve at least 20% excess weight loss (%EWL) from implant to end of the study period.
Experience no serious or severe adverse events related to the device or the procedure
No significant negative change in quality of life using the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>12 months</time_frame>
    <description>Fifty (50 %) of the subject population must obtain an EWL ≥ 25%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence and seriousness of all adverse events.
Incidence of device or procedure-related adverse events
Frequency of clinically significant abnormal laboratory values as determined by the Investigator;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Frequency of device and procedure-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Change in the quality of life using the IWQOL-Lite questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Behavior</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Change in the eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-morbid Conditions</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Evaluation of the changes in blood pressure, lipid panel, HbA1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Obesity</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>abiliti Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Band Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>abiliti system implant</intervention_name>
    <description>Subjects will receive implanted abiliti System.</description>
    <arm_group_label>abiliti Group</arm_group_label>
    <other_name>abiliti</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laparoscopic adjustable gastric band (Allergan Lap Band)</intervention_name>
    <description>Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.</description>
    <arm_group_label>Gastric Band Group</arm_group_label>
    <other_name>gastric band</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 - 60 years old at time of screening

          -  BMI of 40 to 55 or 35 to 39 with an obesity related comorbid condition at time of
             screening

          -  History of obesity ≥5 years

          -  The subject has been under routine care of the investigator or another single
             physician that can supply a medical record for at least 6 months prior to enrollment

          -  Women with childbearing potential (i.e., not post-menopausal or surgically sterilized)
             must agree to use adequate birth control methods

          -  No significant weight loss (&lt;5%) within four months prior to enrollment as documented
             in the subject's medical record.

          -  Successful psychological evaluation following the institution psychological evaluation
             protocol for bariatric surgery or successful historic assessment performed no more
             than 6 months prior to enrollment.

          -  Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more
             than 3 months prior to enrollment.

          -  If taking anti-depressant medications, they must be stable for at least six months
             prior to enrollment

          -  Willingness to refrain from using prescription, over the counter or herbal weight loss
             products for the duration of the trial

          -  Alert, mentally competent, and able to understand and willing to comply with the
             requirements of the clinical trial, and personally motivated to abide by the
             requirements and restrictions of the clinical trial

          -  Able to provide voluntary informed consent

        Exclusion Criteria:

          -  Any prior bariatric surgery

          -  Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator,
             neurostimulator)

          -  Diagnosed with past or current psychiatric condition that may impair his/her ability
             to comply with the study procedures

          -  Use of anti-psychotic medications

          -  Diagnosed with a eating disorder such as bulimia or binge eating

          -  Obesity due to an endocrinopathy (e.g. Cushing disease)

          -  Insulin therapy

          -  GI disease such as hiatal hernia (&gt;5cm), gastroparesis, esophageal motility disorders
             or intractable constipation.

          -  Cirrhosis, chronic pancreatitis

          -  History of intestinal obstruction or adhesive peritonitis

          -  Any history of peptic ulcer disease within 5 years prior to enrollment

          -  Women who are pregnant, lactating or anticipate becoming pregnant within 24 months

          -  Arthritis or other pathologies limiting physical activities that physician feels
             should exclude the patient from the study.

          -  Chronic use of aspirin and/or non steroidal anti-inflammatory medications and
             unwillingness to discontinue use

          -  Cardiac history that physician feels should exclude the patient from the study.

          -  Concurrent use of weight loss medications.

          -  Use of another investigational device or agent in the 30 days prior to enrollment

          -  A history of life-threatening disease within 5 years prior to enrollment

          -  Any other condition that, in the opinion of the investigator, would make the subject
             unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Horbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stadtkrankenhaus Schwabach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberic Fiennes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Anthony's Hospital, Surrey, England</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Nardelli</last_name>
    <phone>650-316-4065</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Polyclinique de Rillieux, Clinique Lyon-Nord</name>
      <address>
        <city>RILLIEUX Cedex</city>
        <zip>69165</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Dargent, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jerome Dargent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MIC Ev. Krankenhaus Hubertus</name>
      <address>
        <city>Berlin</city>
        <zip>14129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Susewind, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Susewind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Stroh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine Stroh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfart Klinik</name>
      <address>
        <city>Graefelfing</city>
        <zip>92166</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Mann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oliver Mann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtkrankenhaus Schwabach</name>
      <address>
        <city>Schwabach</city>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Horbach, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Horbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera- University</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Anselmino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Anselmino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica San Luca Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe M Rovera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe M Rovera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vicenza Regional Hospital</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franco Favretti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franco Favretti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complutense University of Madrid Hospital Clinico &quot;San Carlos&quot;</name>
      <address>
        <city>Madrid</city>
        <zip>28290</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio J Torres, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio J Torres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Roció</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Morales Conde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Salvador Morales Conde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Lindberg</name>
      <address>
        <city>Winterthur</city>
        <zip>8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fritz Horber, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fritz Horber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spire Southampton Hospital</name>
      <address>
        <city>Hampshire</city>
        <state>Southampton</state>
        <zip>SO16 6UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Byrne, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anthony's Hospital</name>
      <address>
        <city>North Cheam</city>
        <state>Surrey</state>
        <zip>SM3 9DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberic Fiennes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberic Fiennes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Yorkshire NHS Trust</name>
      <address>
        <city>Dewsbury</city>
        <state>West Yorkshire</state>
        <zip>WF13 4HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chinnadorai Rajeswaran, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chinnadorai Rajeswaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>gastric stimulation</keyword>
  <keyword>morbid obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

